



Update on active U.S. Study Sites for Azafaros' Phase 3 clinical Trial NAVIGATE

The National Niemann-Pick Disease Foundation (NNPDF) is hereby informing the community on the opening of the next U.S. study sites for the Phase 3 Navigate clinical trial, sponsored by Azafaros.

Navigate is a double-blind placebo-controlled study, investigating the safety and efficacy of oral nizubaglustat, an investigational product designed for the treatment of late - infantile/juvenile forms of Niemann-Pick type C disease and GM1 and GM2 (Tay Sachs and Sandhoff disease).

Since the opening of the first study site in the U.S. in Oakland California in February other centers were activated and two other centers will follow in the upcoming months.

ACTIVE SITES:

Oakland, California

Children's Hospital and Research Center, Dr. Hastings

Fairfax, Virginia

Lysosomal Rare Disorders Research and Treatment Center, Dr. Goker-Alpan

Rochester, Minnesota

Mayo Clinic, Dr. Dhamija

Additional U.S. sites for the Navigate trial are expected to open in the upcoming weeks.

Dallas, Texas

Children's Medical Center of Dallas, Dr. Ramirez

Minneapolis, Minnesota

University of Minnesota Medical School, Dr. Jarnes

If you are interested to participate you can reach out to your care team and ask for a referral to one of the study sites. Or reach out to the NNPDF for more information.

For more information about the study www.navigate.azafaros.com

For more information on the study and on site participation, please visit <https://clinicaltrials.gov/study/NCT07082725>